

# Assessing and Managing Chronic Non-Cancer Pain

## Supplemental Resource Library

CADTH collaborated with the New Brunswick Department of Health, New Brunswick Medical Society, and Choosing Wisely New Brunswick to develop the e-Learning module Assessing and Managing Chronic Non-Cancer Pain. As a supplement to the content, a selection of additional guidelines, resources, courses, and references are provided.

### Guidelines

**2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain**

- [McMaster Michael G DeGroot National Pain Centre Guidelines](#)
- [Appendix 1 + MagicApp Application](#) (Interactive Format)
- [CMAJ Guideline Summary](#)

**CRISM National Guideline for the Clinical Management of Opioid Use Disorder**

- [National Opioid Use Disorder Guideline and Recommendations at a Glance](#)

### Resources

**CADTH**

- [Evidence Bundle – Opioids](#)
- [Evidence Bundle – Pain Management](#)
- [Non-Drug Ways to Manage Chronic Pain](#)
- [Opioid Prescribing and Pain Management: Prescription Monitoring Program Overview and the Management of Acute Low Back Pain](#)
- [Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan](#)

---

**Centre for Effective Practice**

- [Opioid Manager + Appendix](#)
- [Opioid Tapering Template](#)
- [Management of Chronic Non-Cancer Pain](#)
- [Clinically Organized Relevant Exam \(CORE\) Back Tool](#)
- [Chronic Non-Cancer Pain in the COVID-19 Context](#)

---

**McMaster University  
National Pain Centre**

- [Opioid Manager](#)

---

**The College of Family  
Physicians of Canada**

- [Chronic non-cancer pain management and opioid resources](#)

---

**Choosing Wisely Canada**

- [Opioid Wisely](#)
- [Choosing Wisely New Brunswick - Opioids](#)

---

**Health Quality Ontario**

- [Quality Standard – Opioid Prescribing for Chronic Pain](#)
- [Ontario Pain Management Resources](#)

---

**New Brunswick Medical  
Society**

- [Let's Talk Opioids](#)
- [Patient Service Directory](#)
- [Provider resources](#)

---

**The Institute for Safe  
Medication Practices  
Canada**

- [Buprenorphine/Naloxone for Opioid Use Disorder: Your Questions Answered](#)
- [Methadone for Opioid Use Disorder: Your Questions Answered](#)
- [Resources on Opioid Stewardship](#)

---

**Canadian Deprescribing  
Network**

- [Opioid Tapering Protocol](#)
  - [Deprescribing Opioids \(video\)](#)
  - [EMPOWER brochure on opioids/narcotics](#)
-

- 
- RxFiles** • [Various opioid and chronic non-cancer pain related tools and resources](#) (paid)
- 

## Courses

- University Health Network** • [Online Self-Assessment Program \(SAP\) of Opioids for Chronic Non-Cancer Pain](#)
- 

- McMaster University** • [Machealth Opioids Clinical Primer](#)
- 

- University of Toronto** • [Safer Opioid Prescribing](#)
- 

## Additional References

### Current Canadian Context

1. Health Canada. Canadian Pain Task Force Report: September 2020. Published November 6, 2020. Accessed March 5, 2021. <https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2020.html>
2. Opioids in Canada | CIHI. Accessed March 5, 2021. <https://www.cihi.ca/en/opioids-in-canada>
3. Opioid- and Stimulant-related Harms in Canada. Accessed March 5, 2021. <https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/>
4. Opioid prescribing practices changing in Canada | CIHI. Accessed March 5, 2021. <https://www.cihi.ca/en/opioid-prescribing-practices-changing-in-canada>
5. Health Canada. Data, surveillance and research on opioids and other substances. Published December 22, 2017. Accessed March 5, 2021. <https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/data-surveillance-research.html>
6. Health Canada. Modelling opioid overdose deaths during the COVID-19 outbreak. Published November 26, 2020. Accessed March 4, 2021. <https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/data-surveillance-research/modelling-opioid-overdose-deaths-covid-19.html>
7. Busse JW, Douglas J, Chauhan TS, Kobeissi B, Blackmer J. Perceptions and Impact of the 2017 Canadian Guideline for Opioid Therapy and Chronic Noncancer Pain: A Cross-Sectional Study of Canadian Physicians. *Pain Research and Management*. doi:<https://doi.org/10.1155/2020/8380171>
8. Furlan AD, Diaz S, Carol A, MacDougall P, Allen M. Self-Reported Practices in Opioid Management of Chronic Noncancer Pain: An Updated Survey of Canadian Family Physicians. *J Clin Med*. 2020;9(10). doi:10.3390/jcm9103304

### Classification of Pain

9. Shraim MA, Massé-Alarie H, Hodges PW. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a systematic review. *Pain*. 2021;162(4):1007-1037. doi:10.1097/j.pain.0000000000002113
10. Shraim MA, Massé-Alarie H, Hall LM, Hodges PW. Systematic Review and Synthesis of Mechanism-based Classification Systems for Pain Experienced in the Musculoskeletal System. *Clin J Pain*. 2020;36(10):793-812. doi:10.1097/AJP.0000000000000860

11. Kolski MC, O'Connor A, Van Der Laan K, Lee J, Kozlowski AJ, Deutsch A. Validation of a pain mechanism classification system (PMCS) in physical therapy practice. *J Man Manip Ther.* 2016;24(4):192-199. doi:10.1179/2042618614Y.0000000090
12. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back ( $\pm$  leg) pain. *Man Ther.* 2012;17(4):336-344. doi:10.1016/j.math.2012.03.013
13. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 2 of 3: symptoms and signs of peripheral neuropathic pain in patients with low back ( $\pm$  leg) pain. *Man Ther.* 2012;17(4):345-351. doi:10.1016/j.math.2012.03.003
14. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back ( $\pm$  leg) pain. *Man Ther.* 2012;17(4):352-357. doi:10.1016/j.math.2012.03.002
15. Smart KM, Blake C, Staines A, Doody C. The Discriminative validity of "nociceptive," "peripheral neuropathic," and "central sensitization" as mechanisms-based classifications of musculoskeletal pain. *Clin J Pain.* 2011;27(8):655-663. doi:10.1097/AJP.0b013e318215f16a
16. Smart KM, Blake C, Staines A, Doody C. Clinical indicators of "nociceptive," "peripheral neuropathic" and "central" mechanisms of musculoskeletal pain. A Delphi survey of expert clinicians. *Man Ther.* 2010;15(1):80-87. doi:10.1016/j.math.2009.07.005
17. Smart KM, Curley A, Blake C, Staines A, Doody C. The reliability of clinical judgments and criteria associated with mechanisms-based classifications of pain in patients with low back pain disorders: a preliminary reliability study. *J Man Manip Ther.* 2010;18(2):102-110. doi:10.1179/106698110X12640740712897

## Managing Chronic Non-Cancer Pain During COVID-19

18. Canadian Pain Network. Canadian Research into COVID-19. Accessed March 5, 2021.
19. Health Canada. Helping people who use substances during the COVID-19 pandemic. Published September 1, 2020. Accessed March 5, 2021. <https://www.canada.ca/en/health-canada/services/substance-use/helping-people-who-use-substances-covid-19.html>
20. Shanthanna H, Strand NH, Provenzano DA, et al. Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. *Anaesthesia.* 2020;75(7):935-944. doi:https://doi.org/10.1111/anae.15076
21. Canadian Research Initiative in Substance Misuse (CRISM). COVID-19 Pandemic - National Rapid Guidance. Accessed March 5, 2021. <https://crism.ca/projects/covid/>
22. Health Canada. COVID-19 and substance use: Service provider toolkit. Published December 9, 2020. Accessed March 5, 2021. <https://www.canada.ca/en/health-canada/services/substance-use/toolkit-substance-use-covid-19.html>
23. Health Canada. Resources for Canadians living with pain during COVID-19. Published July 29, 2020. Accessed March 5, 2021. <https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/resources.html>
24. Impacts of COVID-19 on Substance Use | Canadian Centre on Substance Use and Addiction. Accessed March 5, 2021. <https://www.ccsa.ca/Impacts-COVID-19-Substance-Use>

## Questions or comments about CADTH or this tool?



Online:  
[cadth.ca](https://cadth.ca)



Email:  
[requests@cadth.ca](mailto:requests@cadth.ca)



Twitter:  
[@CADTH\\_ACMTS](https://twitter.com/CADTH_ACMTS)



New at CADTH Newsletter:  
[cadth.ca/subscribe](https://cadth.ca/subscribe)

### DISCLAIMER

This material is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose; this document should not be used as a substitute for professional medical advice or for the application of professional judgment in any decision-making process. Users may use this document at their own risk. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not guarantee the accuracy, completeness, or currency of the contents of this document. CADTH is not responsible for any errors or omissions, or injury, loss, or damage arising from or relating to the use of this document and is not responsible for any third-party materials contained or referred to herein. Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information. This document is subject to copyright and other intellectual property rights and may only be used for non-commercial, personal use or private research and study.

### ABOUT CADTH

CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

October 2021

**CADTH** Evidence  
Driven.

[cadth.ca](https://cadth.ca)